“Global Bioreactors market set to grow to $1.6bn by 2024” says new Visiongain report

18 December 2018
Pharma

Visiongain has launched a new pharma report Global Bioreactors Market 2019-2029: 5L-20L, 20L-200L, 200L-1500L, Above 1500L, Single-Use, Glass, Stainless Steel, Lab-Scale, Pilot-Scale, Full-Scale, R&D Departments, Biopharmaceutical Manufacturers, Contract Research Organizations, Other End-Users.

The biopharmaceutical contract manufacturing market has significantly expanded over the past years. The rising interest of pharmaceutical organizations to enter the biopharmaceutical market will result in consolidation in the form of strategic alliances between contract manufacturing organizations (CMO’s) and large pharmaceutical/biotechnology organizations. This will result in increased investments and access to cutting-edge manufacturing technologies for CMOs.

Factors driving the bioreactors market growth include massive use of hybrid technologies, rise in the rate of adoption of single-use technologies, increasing popularity of single-use bioreactor among biopharmaceutical organizations, and a significant growth in the biologics market. However, regulatory challenges pertaining to single-use bioreactors and issues concerning leachable and extractable linked to single-use bags are some of the factors hampering the growth of bioreactors market.

The lead analyst of the report commented "There has been an unprecedented growth in the biologics and biosimilars market over the past years and these markets are likely to grow at double digit growth rate in the future years.

Therefore, owing to the expectations for robust growth in the biologic drugs demand, large number of manufacturers, including branded and biosimilar drug producers, are increasingly investing in the setting-up of new production facilities."

Leading companies featured in the report include Applikon Biotechnology Inc. (U.S.), BBI-Biotech GmbH (Germany), Bioengineering AG (Switzerland), Danaher Corporation (U.S), Eppendorf AG (Germany), GE Healthcare (A subsidiary of General Electric Company) (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Solaris Biotech (Italy), Thermo Fisher Scientific, Inc. (U.S.)

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever